ANN ARBOR, MI, UNITED STATES, – GreenMark Biomedical Inc., a pioneer in leveraging biomimetic technology for dental health innovations…………

Genomenon Genomic Graph (G3) knowledgebase combines patient and biological data from nearly all published scientific and medical studies, including demographics, clinical characteristics, phenotypes, treatments, outcomes, and disease-associated genes and variants.

‍

●      Training of the underlying large language model (LLM) for G3 uses Genomenon’s proprietary, expertly curated genomic datasets to deliver unprecedented model accuracy 

‍

●      The knowledgebase will power AI-driven predictive models of unparalleled accuracy, breadth, and complexity for clinical diagnostics and drug development applications 

‍

Ann Arbor, MI – December 17, 2024 – Genomenon, Inc., a leading provider of genomic intelligence solutions, today announced the company has used the industry’s most advanced genomic AI platform to build the Genomenon Genomic Graph (G3) knowledgebase of all clinically relevant, empirical genomic evidence. This advancement represents the first time that content from the entire corpus of clinically relevant literature will be captured in a single, searchable knowledgebase. 

‍

The knowledgebase will include genes, genetic variants, copy number variants, structural variants including fusion events, gene-disease relationships, drugs, phenotypes, and patient demographics and symptoms derived from the indexed content of the published scientific research. In addition to enabling advanced biomedical literature search and aler

NEW YORK – In acquiring longtime partner Boston Genomics this week, Genomenon is stepping up its efforts to become the first entity to curate the entire human genome, though it may be the only one to have declared such an intention.

By adding Cambridge, Massachusetts-based Boston Genetics’ team of about 75 genetic scientists — and doubling its total headcount — Genomenon now claims to have an inside track toward its goal, which CEO Mike Klein said is intended to combine artificial intelligence and next-generation sequencing to accelerate diagnosis of rare diseases and inform drug discovery.

“We’ll organize all the disease-gene relationships, we’ll organize all the variant landscapes across every disease, to really provide the insight for precision medicine,” Klein said.

While nobody else has publicly declared a similar intention, Klein has been talking about a “race” to curate the complete human genome, and the firm has been on this mission for several years on the back of its flagship product, the AI-powered Mastermind Genomic Search Engine.

Genomenon’s focus has evolved from building an AI-enabled genomic search engine to curating the human genome. The firm has added AI curation tools, augmented by human expertise as necessary, as it has grown in the pharma marketplace.

The company has now indexed 22 million variants by combing entries from the medical literature, a number that is growing because Mastermind’s AI is “ingesting” and reviewing about 750,000 new scientific articles per year, according to Klein. “No human